Vanguard Portfolio Management
ELDN icon

Vanguard Portfolio Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Vanguard Portfolio Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
533,365
+103,476
+24% +$376K ﹤0.01% 2714
2026
Q1 		$1.32M Buy
+429,889
New +$1.01M ﹤0.01% 2712

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Vanguard Portfolio Management's ELDN Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Eledon Pharmaceuticals (ELDN) stake by 24% in Q2 2026, buying an estimated $376K and bringing the position to 533,365 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2714.

Vanguard Portfolio Management first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Vanguard Portfolio Management held 533,365 shares of Eledon Pharmaceuticals worth $2.1M as of Q2 2026.
  • Vanguard Portfolio Management bought 103,476 Eledon Pharmaceuticals shares in Q2 2026, an estimated $376K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2714 holding.
  • Vanguard Portfolio Management first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.